110 related articles for article (PubMed ID: 12646686)
1. Site-specific mutagenesis in a homogeneous polyglutamine tract: application to spinocerebellar ataxin-3.
Chen YW
Protein Eng; 2003 Jan; 16(1):1-4. PubMed ID: 12646686
[TBL] [Abstract][Full Text] [Related]
2. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
[TBL] [Abstract][Full Text] [Related]
3. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
4. Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation.
Nozaki K; Onodera O; Takano H; Tsuji S
Neuroreport; 2001 Oct; 12(15):3357-64. PubMed ID: 11711886
[TBL] [Abstract][Full Text] [Related]
5. Conserved domains and lack of evidence for polyglutamine length polymorphism in the chicken homolog of the Machado-Joseph disease gene product ataxin-3.
Linhartová I; Repitz M; Dráber P; Nemec M; Wiche G; Propst F
Biochim Biophys Acta; 1999 Feb; 1444(2):299-305. PubMed ID: 10023088
[TBL] [Abstract][Full Text] [Related]
6. Mosaicism of the CAG repeat in CNS tissue in relation to age at death in spinocerebellar ataxia type 1 and Machado-Joseph disease patients.
Maciel P; Lopes-Cendes I; Kish S; Sequeiros J; Rouleau GA
Am J Hum Genet; 1997 Apr; 60(4):993-6. PubMed ID: 9106546
[No Abstract] [Full Text] [Related]
7. Cell cycle arrest enhances the in vitro cellular toxicity of the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.
Yoshizawa T; Yamagishi Y; Koseki N; Goto J; Yoshida H; Shibasaki F; Shoji S; Kanazawa I
Hum Mol Genet; 2000 Jan; 9(1):69-78. PubMed ID: 10587580
[TBL] [Abstract][Full Text] [Related]
8. Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3.
Gales L; Cortes L; Almeida C; Melo CV; Costa MC; Maciel P; Clarke DT; Damas AM; Macedo-Ribeiro S
J Mol Biol; 2005 Oct; 353(3):642-54. PubMed ID: 16194547
[TBL] [Abstract][Full Text] [Related]
9. Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing.
McIntosh CS; Aung-Htut MT; Fletcher S; Wilton SD
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31683630
[TBL] [Abstract][Full Text] [Related]
10. Analysis of CAG repeat of the Machado-Joseph gene in human, chimpanzee and monkey populations: a variant nucleotide is associated with the number of CAG repeats.
Limprasert P; Nouri N; Heyman RA; Nopparatana C; Kamonsilp M; Deininger PL; Keats BJ
Hum Mol Genet; 1996 Feb; 5(2):207-13. PubMed ID: 8824876
[TBL] [Abstract][Full Text] [Related]
11. [Detection of the CAG trinucleotide repeats of MJD1 gene by recombinant DNA technology].
Zhang S; Wang JL; Xu Q; Li XH; Lei LF; Jiang H; Shen L; Yan XX; Pan Q; Xia K; Tang BS
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Aug; 26(4):406-9. PubMed ID: 20017304
[TBL] [Abstract][Full Text] [Related]
12. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation.
Perez MK; Paulson HL; Pendse SJ; Saionz SJ; Bonini NM; Pittman RN
J Cell Biol; 1998 Dec; 143(6):1457-70. PubMed ID: 9852144
[TBL] [Abstract][Full Text] [Related]
13. Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix.
Perez MK; Paulson HL; Pittman RN
Hum Mol Genet; 1999 Dec; 8(13):2377-85. PubMed ID: 10556285
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous intracellular localization and expression of ataxin-3.
Trottier Y; Cancel G; An-Gourfinkel I; Lutz Y; Weber C; Brice A; Hirsch E; Mandel JL
Neurobiol Dis; 1998 Nov; 5(5):335-47. PubMed ID: 10069576
[TBL] [Abstract][Full Text] [Related]
15. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Matos CA; de Macedo-Ribeiro S; Carvalho AL
Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
[TBL] [Abstract][Full Text] [Related]
16. Polyglutamine-Independent Features in Ataxin-3 Aggregation and Pathogenesis of Machado-Joseph Disease.
Carvalho AL; Silva A; Macedo-Ribeiro S
Adv Exp Med Biol; 2018; 1049():275-288. PubMed ID: 29427109
[TBL] [Abstract][Full Text] [Related]
17. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo.
Ikeda H; Yamaguchi M; Sugai S; Aze Y; Narumiya S; Kakizuka A
Nat Genet; 1996 Jun; 13(2):196-202. PubMed ID: 8640226
[TBL] [Abstract][Full Text] [Related]
18. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
[TBL] [Abstract][Full Text] [Related]
19. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics.
Scheel H; Tomiuk S; Hofmann K
Hum Mol Genet; 2003 Nov; 12(21):2845-52. PubMed ID: 12944423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
